Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus Inc. (NASDAQ: AGEN) has initiated the dosing of its first patient with agenT-797, an allogeneic iNKT cell therapy targeting moderate to severe COVID-19. This innovative therapy aims to eliminate the SARS-CoV-2 virus while curbing excessive inflammation. Additionally, the FDA has approved agenT-797 for cancer treatment, and trials for cancer patients are expected to begin soon. Agenus emphasizes its unique combination of therapies and cost-effectiveness in addressing critical health issues.
Agenus Inc. (NASDAQ: AGEN) provided a corporate update alongside its Q3 2020 financial results. The company initiated its rolling BLA filing for Balstilimab, with FDA review in progress. Recent clinical trials show Balstilimab achieving a 19% response rate in PD-L1 positive tumors and a combination with zalifrelimab yielding 27%. The cash balance rose to $114 million, while Q3 net loss was $52 million, a slight increase from $46 million in Q3 2019. Revenues totaled $14.8 million, down from $19.9 million in the prior year. New data on AGEN1181 will be presented at the upcoming SITC meeting.
Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020. A conference call and webcast will follow at 8:30 AM ET for a discussion of the results and corporate update. Agenus specializes in immuno-oncology with an extensive pipeline including checkpoint antibodies, cell therapies, and vaccines aimed at enhancing immune responses to cancer and infections. The call will be accessible via the company’s website.
Agenus Inc. (NASDAQ: AGEN) announced the acceptance of seven abstracts for the virtual SITC 2020 Annual Meeting, scheduled for November 9-14, 2020. Key presentations include:
- AGEN1181: Demonstrates clinical activity as a standalone or in combination with balstilimab.
- Zalifrelimab: Shows clinical benefit in rare tumors.
- AGEN2373: A CD137 agonist antibody targeting antitumor effects.
- AgenT-797: A novel cell therapy promoting tumor killing.
Updated data will be available on the Agenus website post-conference.
Agenus Inc. (NASDAQ: AGEN) announced the election of Susan Hirsch to its Board of Directors, a significant move as the company prepares for its initial commercial product launches. Garo Armen, Chairman and CEO, praised Hirsch's extensive experience, particularly in identifying high-value companies at critical growth stages. With over 40 years in investment management, including a leadership role at Nuveen, Hirsch's expertise is expected to enhance Agenus' strategic direction. The company is focused on developing therapies that engage the immune system to combat cancer.
Agenus Inc. (NASDAQ: AGEN) announced the initiation of the rolling submission of its Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, to the FDA for treating recurrent/metastatic cervical cancer. Results from a significant phase 2 trial indicated response rates of 19% in PD-L1 positive patients and 14% overall. The rolling BLA submission allows for concurrent FDA review of each section as it is completed. The American Cancer Society reported around 14,000 new cervical cancer cases expected this year, highlighting the need for new therapies.
Agenus Inc. (NASDAQ: AGEN) reported preliminary results from two Phase 2 clinical trials at the ESMO Virtual Congress 2020, focusing on recurrent/metastatic cervical cancer. The balstilimab monotherapy trial showed a 14% response rate overall and 19% in PD-L1 positive patients. The combination of balstilimab and zalifrelimab achieved a 22% overall response rate and 27% in PD-L1 positive patients. Notably, the median duration of response was 15.4 months for balstilimab alone. Both therapies show potential as new options for patients with limited treatment choices.
Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, participated in a fireside chat series with Scientific American on September 16, 2020. Dr. Buell discussed Agenus’ immunotherapy innovations in combating COVID-19, emphasizing the significance of combination therapies and improving patient access. The replay of the event is accessible online. Agenus, a clinical-stage immuno-oncology company, aims to enhance patient outcomes through a variety of therapeutic approaches, including antibody therapeutics and cancer vaccine platforms.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company, will host a webcast on September 21, 2020, at 2:30 p.m. ET featuring Dr. David O’Malley, who will discuss the data on balstilimab and zalifrelimab presented at ESMO. The session will cover the largest clinical trials concerning refractory cervical cancer and the future of this proprietary combination therapy. Additional discussions will involve progress on Agenus' pipeline assets, including AGEN1181 and various TIGIT therapies. A replay will be available on Agenus’ website.
Agenus Inc. (NASDAQ: AGEN) announced the election of Paul Clark to its Board of Directors on August 31, 2020. Clark brings over 30 years of experience in the pharmaceutical and biotech industries, including leadership roles at ICOS and Abbott Laboratories. His expertise is expected to aid Agenus in transitioning to a commercial company as it prepares for the launch of its first immuno-oncology antibodies. Chairman and CEO Garo Armen highlighted Clark's valuable insights, anticipating positive impacts from his extensive experience in product development and commercialization.